- Home
- TAL vs IONS Comparison
TAL vs IONS Comparison
Compare TAL & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAL
- IONS
- Stock Information
- Founded
- TAL 2003
- IONS 1989
- Country
- TAL China
- IONS United States
- Employees
- TAL N/A
- IONS N/A
- Industry
- TAL Other Consumer Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- TAL Real Estate
- IONS Health Care
- Exchange
- TAL Nasdaq
- IONS Nasdaq
- Market Cap
- TAL 6.3B
- IONS 5.9B
- IPO Year
- TAL 2010
- IONS 1991
- Fundamental
- Price
- TAL $10.34
- IONS $37.41
- Analyst Decision
- TAL Buy
- IONS Buy
- Analyst Count
- TAL 4
- IONS 18
- Target Price
- TAL $13.12
- IONS $57.59
- AVG Volume (30 Days)
- TAL 6.4M
- IONS 1.5M
- Earning Date
- TAL 07-31-2025
- IONS 07-31-2025
- Dividend Yield
- TAL N/A
- IONS N/A
- EPS Growth
- TAL N/A
- IONS N/A
- EPS
- TAL 0.14
- IONS N/A
- Revenue
- TAL $2,250,233,000.00
- IONS $717,253,000.00
- Revenue This Year
- TAL $33.54
- IONS $7.98
- Revenue Next Year
- TAL $24.09
- IONS $16.09
- P/E Ratio
- TAL $75.93
- IONS N/A
- Revenue Growth
- TAL 50.98
- IONS N/A
- 52 Week Low
- TAL $7.35
- IONS $23.95
- 52 Week High
- TAL $15.30
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- TAL 47.70
- IONS 68.61
- Support Level
- TAL $10.21
- IONS $34.78
- Resistance Level
- TAL $10.67
- IONS $37.54
- Average True Range (ATR)
- TAL 0.27
- IONS 1.06
- MACD
- TAL -0.03
- IONS 0.07
- Stochastic Oscillator
- TAL 44.63
- IONS 95.44
About TAL TAL Education Group
TAL Education Group is a smart learning solutions provider in China. It operates a few business lines including enrichment learning, high school academic tutoring, learning technology, and content solutions. Among those business lines, TAL focuses on enrichment learning and content solutions.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.